MK2206 in Combination with selected Chemotherapies

• Research type

  Research Study

• Full title

  A Phase I Dose Escalation Study of MK-2206 in Combination with Standard Doses of Selected Chemotherapies or Targeted Agents in Patients with Locally Advanced or Metastatic Solid Tumors

• IRAS ID

  17514

• Sponsor organisation

  Merck & Co. Inc.

• Eudract number

  2008-008994-73

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  MK-2206 is an experimental drug that blocks a signalling protein called Akt and is being tested for the treatment of cancer. The abnormal activation of Akt is a suspected driver of many human cancers. Drugs that block the abnormal signalling of Akt may thus be a new way of treating cancer.The study will look at the safety and effectiveness of MK2206 in combination with selected chemotherapy and targeted agents in adult patients with locally advanced or metastatic solid tumours.

• REC name

  London - Chelsea Research Ethics Committee

• REC reference

  09/H0801/45

• Date of REC Opinion

  26 Jun 2009

• REC opinion

  Further Information Favourable Opinion